Latest News

 Filter by Provider

FOX CORP (NASDAQ:FOXA) appears undervalued with strong profitability, solid financial health, and reasonable growth, making it a potential pick for value investors.

GLOBUS MEDICAL (NYSE:GMED) is a strong growth stock with reasonable valuation, solid profitability, and a healthy balance sheet, making it an attractive option for investors seeking growth at a fair price.

VIPSHOP HOLDINGS (NYSE:VIPS) offers growth at a reasonable price, with strong profitability, low debt, and a PEG of 0.36. A potential GARP pick for long-term investors.

CATALYST PHARMACEUTICALS (CPRX) offers strong growth, solid profitability, and an attractive valuation, making it a standout in biotech.

META PLATFORMS (NASDAQ:META) meets key quality investing criteria with strong growth, high ROIC, and solid financials, making it a stock worth considering for long-term investors.

ALTRIA GROUP INC (NYSE:MO) offers a high 6.86% dividend yield, strong profitability, and reasonable valuation, making it a candidate for dividend investors.

BRIGHTSPRING HEALTH SERVICES (NASDAQ:BTSG) shows strong technicals and a high-quality setup, making it a stock to watch for potential breakout traders.

Coupang is executing its way to become the Amazon of South Korea.

SPROUTS FARMERS MARKET (NASDAQ:SFM) shows strong earnings momentum, expanding margins, and a bullish technical setup, making it a candidate for growth investors.

WAYSTAR HOLDING CORP (NASDAQ:WAY) shows strong earnings momentum and a solid technical setup, making it a candidate for high-growth investors. The stock has rising EPS, expanding margins, and bullish price trends.

TRAVEL + LEISURE CO (NYSE:TNL) appears undervalued with strong liquidity, stable profitability, and a high dividend yield. Future earnings growth could drive further upside.

XPEL INC (NASDAQ:XPEL) offers strong growth, solid profitability, and reasonable valuation, making it a candidate for GARP investors following Peter Lynch’s strategy.

Each of the index's highest-yielding names has its own unique story right now.

In a heated debate on Piers Morgan Uncensored, Scott Galloway criticized Elon Musk's personal behavior while Kevin O'Leary defended his technological achievements, with Galloway saying, "I think the two of you are more impressed with Mr. Musk than I am."

ADMA Biologics (NASDAQ:ADMA) shows strong earnings momentum and a favorable technical setup, making it a candidate for high-growth investors. The stock has outperformed peers and may present a breakout opportunity.

All of the factors align for this company to split its shares, but it's a buy no matter what.

Are you ready for C-3PO to ring your doorbell?

With the streaming-TV company's stock price soaring about 40% higher this year, a stock split seems inevitable -- and it could come soon.